Last reviewed · How we verify
NCT05110898: OLINDA
Efficacy and Safety Study of the Fixed-dose Combination of Olmesartan + Indapamide When Compared to the Isolated Drugs in the Treatment of Hypertension.
Phase 3 trial testing fixed-dose of olmesartan 20mg/40 mg + indapamide 1,5 mg in Hypertension in 400 participants. Status unknown.
1 August 2023
Quick facts
| Lead sponsor | Brainfarma Industria Química e Farmacêutica S/A |
|---|---|
| Phase | Phase 3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 400 |
| Start date | 1 August 2022 |
| Primary completion | 1 August 2023 |
| Estimated completion | 1 October 2023 |
Drugs / interventions tested
- fixed-dose of olmesartan 20mg/40 mg + indapamide 1,5 mg — full drug profile →
- Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg) — full drug profile →
Conditions studied
- Hypertension — all drugs for Hypertension →
- Hypertension,Essential — all drugs for Hypertension,Essential →
Sponsor
Brainfarma Industria Química e Farmacêutica S/A — full company profile →
Who can join
18 and older, any sex, with Hypertension or Hypertension,Essential. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Phase III clinical trial, multicenter of non-inferiority, randomized, single-blind evaluation of fixed-dose combination of olmesartan + indapamide compared to the isolated drugs in the treatment of hypertension.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Improving computational drug repositioning through multi-source disease similarity networks.
Le DH. · · 2025 · cited 1× · PMID 40841559 · DOI 10.1038/s41598-025-04772-0
Verify or expand the search:
- PubMed search for NCT05110898
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hypertension
Currently open trials in the same condition.
- NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
- NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
- NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
- NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
- NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting
Other Brainfarma Industria Química e Farmacêutica S/A trials
Trials by the same sponsor.
- NCT05031585 — Efficacy and Safety Study of Nasal Lubricant Compared to Placebo on Snoring · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05110898 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Brainfarma Industria Química e Farmacêutica S/A
- Last refreshed: 21 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05110898.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing